MONOSODIUM GLUTAMATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H7NO4.Na.H.H2O
Molecular Weight	187.1264
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[H+].O.[Na+].N[C@@H](CCC([O-])=O)C([O-])=O

InChI

InChIKey=GJBHGUUFMNITCI-QTNFYWBSSA-M

InChI=1S/C5H9NO4.Na.H2O/c6-3(5(9)10)1-2-4(7)8;;/h3H,1-2,6H2,(H,7,8)(H,9,10);;1H2/q;+1;/p-1/t3-;;/m0../s1

HIDE SMILES / InChI

Molecular Formula	C5H9NO4
Molecular Weight	147.1293
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Glutamic acid is a non-essential aminoacid used in biosynthesis of proteins. Besides being a building block of proteins, glutamic acid plays a principal role in neural activation. Glutamate is also responsible for the umami (savory) flavor of certain foods. In medicine, glutamate is used as a metabolic supplemnet in patients undergoing coronary surgery.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate [NMDA] receptor 125	Agonist 2,752
Glutamate receptor ionotropic kainate 24	Agonist 2,752
Glutamate receptor ionotropic AMPA 42	Agonist 2,752
Metabotropic glutamate receptor 1 25	Agonist 2,752

Conditions

Condition	Modality	Highest Phase	Product
Nerve damage 7	Preventing	Phase III 665	Unknown
Delayed gastric emptying 7	Primary	Not Provided 511	Unknown
Postoperative heart failure 7	Palliative	Phase III 665	Unknown

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-00649	http://www.3bsc.com/index/pro_info.php?id=20861
3B Scientific (Wuhan) Corp	3B3-006381	http://www.3bsc.com/index/pro_info.php?id=28289
AA Blocks	AA00375U	http://www.aablocks.com/goods/Goods/detail?id=AA00375U
Aaron Chemicals	AR0037XM	http://www.aaronchem.com/56-86-0
abcr GmbH	AB116926	http://www.abcr.com/shop/en/AB116926

Showing 1 to 5 of 94 entries

Previous1 2 3 4 5…19Next

PubMed

Show entries

Title	Date	PubMed
Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: a putative animal model of the human fragile X mental retardation syndrome.	2001	12018775
Cooperative helix stabilization by complex Arg-Glu salt bridges.	2001 Aug 1	11391775
Calcium channels triggering transmitter release in the rat medial superior olive.	2001 Dec	11707360
Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase.	2001 Sep	11564640
Distinct signal transduction pathways for GABA-induced GABA(A) receptor down-regulation and uncoupling in neuronal culture: a role for voltage-gated calcium channels.	2001 Sep	11553685

Showing 1 to 5 of 25 entries

Previous1 2 3 4 5Next

Patents

Sample Use Guides

In Vivo Use Guide

As a dietary supplement for taste improvement, glutamate is administered orally with food. Glutamate is administered intravenously in patients undergoing coronary artery bypass surgery.

Route of Administration: Other

In Vitro Use Guide

To study binding of glutamate to AMPA and Kainate ion channels, [3H]APMA and [3H]kainic acid were used as a radioligands.